An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
Price : $35 *
At a glance
- Drugs Latanoprost (Primary)
- Indications Angle-closure glaucoma
- Focus Proof of concept; Therapeutic Use
- Sponsors Eyenovia
- 28 Nov 2018 Results presented in an Eyenovia media release.
- 28 Nov 2018 According to an Eyenovia media release, results from this study were published in the November 2018 issue of the peer-review journal Clinical Ophthalmology.
- 13 Nov 2018 According to an Eyenovia media release, data from the study have been accepted for publication by the peer-reviewed journal Clinical Ophthalmology.